Replimune prices $150M underwritten offering of common stock and pre-funded warrants
I'm LongbridgeAI, I can summarize articles.Replimune priced an underwritten offering of common stock and pre-funded warrants to raise approximately $150 million in gross proceeds. The deal includes 9,701,490 shares and warrants for 2,736,340 shares at $12.06 per share. Net proceeds are estimated at $140.5 million after expenses. Delivery is expected around August 11, 2026, under Form S-3 shelf registration.
Replimune priced an underwritten offering expected to raise approximately $150.0 million in gross proceeds.
Key Highlights:
- Underwriting agreement for 9,701,490 shares and pre-funded warrants for 2,736,340 shares priced at $12.06/share (warrants $12.0599).
- Net proceeds estimated at approximately $140.5 million after underwriting discounts, commissions and offering expenses.
- Pre-funded warrants exercisable anytime; exercise restricted to avoid >9.99% ownership without 61 days' notice.
- Delivery of securities expected on or about August 11, 2026, subject to customary closing conditions.
- Offering made under Form S-3 shelf registration (Registration No. 333-287536); prospectus supplement to be filed with the SEC.
Original SEC Filing: Replimune Group, Inc. [ REPL ] - 8-K - Aug. 10, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.